937263-71-3 Usage
Description
4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylaniline is a chemical compound characterized by its unique molecular structure, which features a triazolo[1,5-α]pyridine moiety linked to a methylaniline group through an oxygen atom. 4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylaniline exhibits specific chemical and biological properties that make it a potential candidate for various applications, particularly in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylaniline is used as a potential therapeutic agent for the treatment of brain cancer. Its unique molecular structure allows it to interact with specific biological targets, such as receptors or enzymes, that play a role in the development and progression of brain tumors. By modulating these targets, the compound may help to inhibit tumor growth, reduce metastasis, and improve patient outcomes.
Additionally, 4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylaniline may also be utilized in the development of novel drug delivery systems, which could enhance its bioavailability, target specificity, and therapeutic efficacy. This could lead to the design of more effective treatments for brain cancer and other related conditions, ultimately improving patient care and quality of life.
Check Digit Verification of cas no
The CAS Registry Mumber 937263-71-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,7,2,6 and 3 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 937263-71:
(8*9)+(7*3)+(6*7)+(5*2)+(4*6)+(3*3)+(2*7)+(1*1)=193
193 % 10 = 3
So 937263-71-3 is a valid CAS Registry Number.
937263-71-3Relevant articles and documents
ALKYNYL QUINAZOLINE COMPOUNDS
-
, (2021/02/19)
The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.
Preparation method of Tucatinib intermediate
-
, (2021/06/06)
The invention discloses a preparation method of a tucatinib intermediate, which comprises the following steps: firstly, reacting 4-chloropyrido-2-amine with N,N-dimethylformamide dimethyl acetal, and then adding hydroxylamine hydrochloride for reaction to
[1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
-
Page/Page column 50; 51, (2021/10/30)
The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I), wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
